Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adelbelimab Neoadjuvant Therapy for HNSCC
NCT06016413Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06016413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016413.